Asia
Ab&B Bio-Tech's Application for Mpox Vaccine Approved in China
Ab&B Bio-Tech's (HKG:2627) investigational new drug application for its mRNA mpox vaccine candidate was approved by China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.Trading in the company's shares, which was suspended April 1, remains suspended.
HKG:2627